Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-08-29

FDA Approved: LAMIVUDINE — Supplemental Application (Rising Pharma Holdings, Inc.)

View source ↗

Summary

FDA approval of a supplemental application for lamivudine by Rising Pharma Holdings, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lamivudine (lamivudine)

Snippet

SUPPL AP for LAMIVUDINE (LAMIVUDINE)